We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Urinary Biomarkers Predict Acute Kidney Injury in Patients with COVID-19

By LabMedica International staff writers
Posted on 08 Nov 2021
Acute kidney injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. More...
AKI causes a build-up of waste products in the blood and makes it hard for the kidneys to keep the right balance of fluid in the body.

Biomarkers of kidney injury, inflammation, and repair may offer further insight beyond current standard methods of characterizing COVID-19-associated. Biomarkers can help to differentiate various types of kidney injury, and may be uniquely helpful in quantifying tubular injury in COVID-19.

Nephrologists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) and their colleagues collected urine samples after a patient’s admission with a confirmed COVID-19 test, with repeat urine sample collections attempted weekly thereafter for patients who remained hospitalized. The team analyzed data from 153 patients hospitalized with COVID-19 treated at two academic medical centers between April 2020 and June 2020.

The scientists selected nine candidate urinary biomarkers as primary exposure variables based on our prior work demonstrating associations of such biomarkers with adverse short and long-term kidney outcomes in other clinical settings. They additionally investigated the association of 10 inflammatory biomarkers with the primary outcome: urinary IL-1β, 2, 4, 6, 8, 10, 12, and 13; tumor necrosis factor alpha (TNF-α); and interferon-γ (IFN-γ).

Urine microscopy scoring was completed in a subset of 59 patients, using the IDEXX SediVue Dx platform (IDEXX Laboratories, Westbrook, ME, USA), with all 59 urine microscopy samples generating an automated report with 70 images each, which were reviewed manually. Urinary albumin and creatinine were measured using the Randox RX Daytona clinical chemistry analyzer (Randox, Crumlin, UK). All other biomarkers were measured using the Meso Scale Discovery (MSD, Rockville, MD, USA) platform.

The investigators reported a 2-fold higher levels of neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), and kidney injury molecule-1 (KIM-1) were associated with increased risk of severe acute kidney injury or death in patients hospitalized with COVID-19. They also noted that subclinical AKI, defined by elevations in urinary biomarkers, was present in 30% to 50% of patients who did not manifest clinical AKI.

The authors concluded that they had identified significant associations between urinary NGAL, KIM-1, MCP-1, and EGF [epidermal growth factor] and the primary outcome of stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission. The discriminatory ability of the individual biomarkers EGF, NGAL, and MCP-1 alone was higher than that of urinary albumin alone and improved in pairwise combinations of these three biomarkers. Neither urine microscopy score nor the presence of viral RNA in the urine of patients with COVID-19 were associated with the primary outcome. The study was published on October 25, 2021 in the American Journal of Kidney Diseases.

Related Links:
Johns Hopkins University School of Medicine
IDEXX Laboratories
Randox
Meso Scale Discovery



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.